XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...
Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th ...
With an approval filing already on the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery. In ...
MUNICH, Aug 31 (Reuters) - Bayer AG is to accelerate the development programme for Xarelto, an anticoagulant that is its most important pipeline product, the German drugmaker said on Sunday. Sign up ...
RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO ® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex ...
LONDON (Reuters) - Bayer AG has launched its new anticoagulant pill Xarelto in Britain and Germany, pricing the product on a par with Sanofi-Aventis's Lovenox injection, the company said on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results